Clarametyx today announced positive topline data from a Phase 1b/2a trial evaluating its novel antibody therapy, CMTX-101, in cystic fibrosis (CF).
MapLight Therapeutics, Inc. (MapLight) (Nasdaq: MPLT) today announced an update to the expected timing of topline results for its ongoing Phase 2 ZEPHYR and IRIS clinical studies, which are ...
Patient-centric trial aiming to evaluate whether bezisterim can help delay disease progression reaches enrollment milestone -- Topline Results ...
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results from its Phase 2 study of suzetrigine, an investigational, oral, highly selective NaV1.8 pain signal ...
Acousia Therapeutics GmbH, a clinical-stage biotechnology company developing treatments for acute and chronic inner ear hearing loss, announced ...
The MARITIME Phase 3 Chronic Weight Management Studies are Actively Enrolling, and Phase 3 Studies in People Living With Atherosclerotic Cardiovascular Disease, Heart Failure and Obstructive Sleep ...
Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. The treatment consisted of two cycles of immunotherapy before ...
Processa Pharmaceuticals (PCSA) reported that it completed the enrollment and dosing of the 20 patients required for the planned formal interim ...
LA JOLLA, Calif.--(BUSINESS WIRE)--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback